&lt;p&gt;Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects&lt;/p&gt;

Dorofeeva, Margarita N; Ших, Е. В.; Sizova, Zhanna M.; Tarasenko, Alisa V; Denisenko, Natalia P.; Смирнов, В. В.; Рыжикова, К. А.; Созаева, Ж. А.; Grishina, Elena A.; Сычев, Д. А.

doi:10.2147/pgpm.s217725

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies showed that omeprazole carries considerable potential for drug interactions because of its high affinity for CYP2C19 and moderate affinity for CYP3A4 [ 34 ]. Dorofeeva et al reported that omeprazole-treated patients with hypertension and acid-related disorders also on long-term amlodipine therapy may lead to a significantly stronger antihypertensive action [ 35 ]. On the other hand, rabeprazole has a weaker potential for interactions than omeprazole, though its interaction profile as compared to esomeprazole has been less extensively investigated [ 34 ].…”

Section: Reviewmentioning

confidence: 99%

Long-Term Use of Proton-Pump Inhibitors: Unravelling the Safety Puzzle

Bhatnagar,

Choudhari,

Pawar

et al. 2024

Cureus

View full text Add to dashboard Cite

Globally, over 25% of the population suffers from acid-related disorders such as dyspepsia or gastroesophageal reflux disease (GERD), and around 7.6% of Indians report having GERD symptoms on a frequent enough basis to warrant a diagnosis. Over the past three decades, proton-pump inhibitors (PPIs) have been the mainstay of medical therapy for acid-peptic diseases like GERD, etc. Additionally, they are frequently prescribed for prophylactic purposes and in conjunction with non-steroidal anti-inflammatory drugs. PPIs are generally prescribed for four to eight weeks. However, it may be prescribed for patients with comorbidities and multiple medications for a longer period of time. While this remains true in terms of effectiveness, concerns have been raised about the safety of long-term PPI use and the serious adverse effects that may result. Some of the observational and population-based cohort studies have shown an association between long-term use of PPIs and an increased risk of pneumonia, major cardiovascular events, dementia, vitamin B12 deficiency, bone fractures, gastric cancer, and kidney injury, among others. This review analyzes the clinical data supporting the long-term use of PPIs and takes a deep dive into whether these several emerging long-term concerns apply to the currently available PPIs in India. We have summarized a vast array of studies, including randomized trials, cohort studies, and meta-analyses, that report low or high incidences of major health risks linked with PPIs and have assessed their appropriateness over a given period.

show abstract

Section: Reviewmentioning

confidence: 99%

Long-Term Use of Proton-Pump Inhibitors: Unravelling the Safety Puzzle

Bhatnagar,

Choudhari,

Pawar

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“… 10 , 15–17 CYP3A4 and CYP3A5 are the two major enzymes of CYP3A family and play important roles in the dehydrogenation of amlodipine. 18 However, it has been reported that CYP3A4 , rather than CYP3A5 , plays a more important role in amlodipine clearance in vivo. 16 However, according to our observations, almost all SNPs of CYP3A4 are very rare in Chinese Han or East Asian.…”

Section: Introductionmentioning

confidence: 99%

Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension

Liang

Zhang

et al. 2021

PGPM

View full text Add to dashboard Cite

Background Amlodipine is one of the most used members of calcium channel blockers (CCB), available to treat hypertension. It is mainly metabolized by the Cytochrome P450 3A4/5 (CYP3A4/5) in the liver. Peripheral edema emerges as the major adverse drug reaction to amlodipine and is the primary reason for discontinuation of amlodipine therapy. However, genetic changes in CYP3A5 may lead to changes in the tolerability of amlodipine. Purpose In this study, we were interested whether variants in CYP3A5 have a role to play in amlodipine-induced peripheral edema. Methods A total number of 240 Chinese Han patients that have experienced hypertension were included in the study. Sixty-four patients had experienced amlodipine-induced peripheral edema, while the remaining 176 patients with no history of edema formed the control group. Twenty-four single-nucleotide polymorphisms (SNPs) of CYP3A5 gene were sequenced by targeted region sequencing method. The relationship of these genetic variants with amlodipine-induced peripheral edema risk was assessed using logistic regression. Results The allele frequencies of CYP3A5*1D (rs15524), CYP3A5*1E (rs4646453) and CYP3A5*3 (rs776746) were significantly different between cases and controls ( P <0.05). The CYP3A5 *3/*3 (CC) or CYP3A5 *1D/*1D (AA) carriers showed an increased risk of amlodipine-induced peripheral edema in dominant model. Meanwhile, patients carrying CYP3A5 *1E (AC/AA) showed a reduced risk of peripheral edema. Furthermore, we found a strong linkage disequilibrium among rs15524, rs4646453 and rs776746. Conclusion Our study reveals for the first time that CYP3A5 *1D, *1E and *3 were associated with amlodipine-induced peripheral edema in Chinese Han patients with hypertension. However, further studies comprising larger number of samples, more related genes and other factors are wanted.

show abstract